Literature DB >> 34138417

Peroxisome proliferator-activated receptor gamma: a novel therapeutic target for cognitive impairment and mood disorders that functions via the regulation of adult neurogenesis.

Juhee Lim1,2, Hyo In Kim1, Yeojin Bang1, Hyun Jin Choi3.   

Abstract

The proliferation, differentiation, and migration of neural precursor cells occur not only during embryonic development but also within distinct regions of the adult brain through the process of adult neurogenesis. As neurogenesis can potentially regulate brain cognition and neuronal plasticity, the factors that enhance neurogenesis can be attractive therapeutic targets for improving cognitive function and regulating neurodegenerative and neuropsychiatric disorders, including affective and mood disorders. Peroxisome proliferator-activated receptors (PPARs) are a class of ligand-activated transcription factors belonging to the nuclear receptor superfamily. PPARγ is a target for insulin sensitizers and plays an essential role in regulating various metabolic processes, including adipogenesis and glucose homeostasis. Interestingly, evidence demonstrates the role of PPARγ activation in regulating neurogenesis. The pharmacological activation of PPARγ using specific ligands increases the proliferation and differentiation of neural stem cells in specific brain regions, including the hippocampus, and prevents neurodegeneration and improves cognition and anxiety/depression-like behaviors in animal models. We summarize here recent reports on the role of PPARγ in adult neurogenesis, as well as the mechanisms involved, and suggest that PPARγ can serve as a potential therapeutic target for neurological and/or neurodegenerative diseases.

Entities:  

Keywords:  Adult neurogenesis; Hippocampus; Nuclear receptor; Peroxisome proliferator-activated receptor

Mesh:

Substances:

Year:  2021        PMID: 34138417     DOI: 10.1007/s12272-021-01333-7

Source DB:  PubMed          Journal:  Arch Pharm Res        ISSN: 0253-6269            Impact factor:   4.946


  102 in total

1.  Hippocampal and prefrontal atrophy in patients with early non-demented Parkinson's disease is related to cognitive impairment.

Authors:  A Brück; T Kurki; V Kaasinen; T Vahlberg; J O Rinne
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-10       Impact factor: 10.154

2.  Early age-related changes in adult hippocampal neurogenesis in C57 mice.

Authors:  Nada M-B Ben Abdallah; Lutz Slomianka; Alexei L Vyssotski; Hans-Peter Lipp
Journal:  Neurobiol Aging       Date:  2008-05-01       Impact factor: 4.673

3.  Pioglitazone reduces mortality, prevents depressive-like behavior, and impacts hippocampal neurogenesis in the 6-OHDA model of Parkinson's disease in rats.

Authors:  Jéssica Mendes Bonato; Taysa Bervian Bassani; Humberto Milani; Maria Aparecida Barbato Frazão Vital; Rúbia Maria Weffort de Oliveira
Journal:  Exp Neurol       Date:  2017-11-21       Impact factor: 5.330

Review 4.  Peroxisome proliferator-activated receptor γ (PPARγ): A master gatekeeper in CNS injury and repair.

Authors:  Wei Cai; Tuo Yang; Huan Liu; Lijuan Han; Kai Zhang; Xiaoming Hu; Xuejing Zhang; Ke-Jie Yin; Yanqin Gao; Michael V L Bennett; Rehana K Leak; Jun Chen
Journal:  Prog Neurobiol       Date:  2017-10-12       Impact factor: 11.685

5.  Neuronal replacement from endogenous precursors in the adult brain after stroke.

Authors:  Andreas Arvidsson; Tove Collin; Deniz Kirik; Zaal Kokaia; Olle Lindvall
Journal:  Nat Med       Date:  2002-08-05       Impact factor: 53.440

6.  PPAR-α agonist fenofibrate protects against the damaging effects of MPTP in a rat model of Parkinson's disease.

Authors:  Janaína K Barbiero; Ronise Santiago; Fernanda S Tonin; Suelen Boschen; Luísa Mota da Silva; Maria Fernanda de Paula Werner; Claudio da Cunha; Marcelo M S Lima; Maria A B F Vital
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2014-03-01       Impact factor: 5.067

7.  Hippocampal granule neuron number and dentate gyrus volume in antidepressant-treated and untreated major depression.

Authors:  Maura Boldrini; Adrienne N Santiago; René Hen; Andrew J Dwork; Gorazd B Rosoklija; Hadassah Tamir; Victoria Arango; J John Mann
Journal:  Neuropsychopharmacology       Date:  2013-01-07       Impact factor: 7.853

8.  Neurotrophic factor-α1 prevents stress-induced depression through enhancement of neurogenesis and is activated by rosiglitazone.

Authors:  Y Cheng; R M Rodriguiz; S R K Murthy; V Senatorov; E Thouennon; N X Cawley; D K Aryal; S Ahn; B Lecka-Czernik; W C Wetsel; Y P Loh
Journal:  Mol Psychiatry       Date:  2014-10-21       Impact factor: 15.992

9.  Cinnamic acid activates PPARα to stimulate Lysosomal biogenesis and lower Amyloid plaque pathology in an Alzheimer's disease mouse model.

Authors:  Sujyoti Chandra; Avik Roy; Malabendu Jana; Kalipada Pahan
Journal:  Neurobiol Dis       Date:  2018-12-19       Impact factor: 5.996

10.  The effects of PPAR-γ agonist pioglitazone on hippocampal cytokines, brain-derived neurotrophic factor, memory impairment, and oxidative stress status in lipopolysaccharide-treated rats.

Authors:  Farimah Beheshti; Mahmoud Hosseini; Milad Hashemzehi; Mohammad Soukhtanloo; Majid Khazaei; Mohammad Naser Shafei
Journal:  Iran J Basic Med Sci       Date:  2019-08       Impact factor: 2.699

View more
  6 in total

1.  Ursolic acid enhances autophagic clearance and ameliorates motor and non-motor symptoms in Parkinson's disease mice model.

Authors:  Yeojin Bang; Yoonjung Kwon; Mihyang Kim; Soung Hee Moon; Kiwon Jung; Hyun Jin Choi
Journal:  Acta Pharmacol Sin       Date:  2022-09-22       Impact factor: 7.169

2.  ERRγ Ligand Regulates Adult Neurogenesis and Depression-like Behavior in a LRRK2-G2019S-associated Young Female Mouse Model of Parkinson's Disease.

Authors:  Hyo In Kim; Juhee Lim; Hyo-Jung Choi; Seok-Ho Kim; Hyun Jin Choi
Journal:  Neurotherapeutics       Date:  2022-05-25       Impact factor: 6.088

3.  Trehalose ameliorates prodromal non-motor deficits and aberrant protein accumulation in a rotenone-induced mouse model of Parkinson's disease.

Authors:  Soung Hee Moon; Young Eun Huh; Hyun Jin Choi; Yoonjung Kwon
Journal:  Arch Pharm Res       Date:  2022-05-26       Impact factor: 6.010

Review 4.  PPARγ Gene Polymorphisms, Metabolic Disorders, and Coronary Artery Disease.

Authors:  Yongyan Song; Shujin Li; Chuan He
Journal:  Front Cardiovasc Med       Date:  2022-03-23

5.  The Small Molecule PPARγ Agonist GL516 Induces Feeding-Stimulatory Effects in Hypothalamus Cells Hypo-E22 and Isolated Hypothalami.

Authors:  Annalisa Chiavaroli; Viviana di Giacomo; Barbara De Filippis; Amelia Cataldi; Claudio Ferrante; Letizia Giampietro
Journal:  Molecules       Date:  2022-07-30       Impact factor: 4.927

6.  Activating PPARβ/δ Protects against Endoplasmic Reticulum Stress-Induced Astrocytic Apoptosis via UCP2-Dependent Mitophagy in Depressive Model.

Authors:  Juan Ji; Shangze Li; Zikai Jiang; Jianbing Yu; Yuqin Sun; Zhenyu Cai; Yinfeng Dong; Xiulan Sun
Journal:  Int J Mol Sci       Date:  2022-09-16       Impact factor: 6.208

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.